{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:31:02Z","timestamp":1793313062398,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002077","name":"Epidermolysis Bullosa Medical Research Foundation","doi-asserted-by":"publisher","award":["RE17763"],"award-info":[{"award-number":["RE17763"]}],"id":[{"id":"10.13039\/100002077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.humimm.2024.110805","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T13:33:28Z","timestamp":1714829608000},"page":"110805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8046-956X","authenticated-orcid":false,"given":"Catherine","family":"Santucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Alexandru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6180-9220","authenticated-orcid":false,"given":"Xinyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemima E","family":"Mellerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia N","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Jack\u00f3w-Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"02","key":"10.1016\/j.humimm.2024.110805_b0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0028-1139665","article-title":"Heredit\u00e4re Anlage zur Blasenbildung (Epidermolysis bullosa hereditaria)","volume":"12","author":"K\u00f6bner","year":"1886","journal-title":"DMW - Dtsch. Med. Wochenschr."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat. Rev. Dis. Primer"},{"issue":"5","key":"10.1016\/j.humimm.2024.110805_b0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjd.20958","article-title":"The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database","volume":"186","author":"Petrof","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility","volume":"183","author":"Has","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"22","key":"10.1016\/j.humimm.2024.110805_b0025","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis bullosa-associated squamous cell carcinoma: from pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0030","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.18128","article-title":"Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa","volume":"182","author":"Has","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2009.03.053","article-title":"Extracutaneous manifestations and complications of inherited epidermolysis bullosa","volume":"61","author":"Fine","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.det.2010.01.004","article-title":"Infection and colonization in epidermolysis bullosa","volume":"28","author":"Mellerio","year":"2010","journal-title":"Dermatol. Clin."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/j.humimm.2024.110805_b0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/01.ASW.0000926608.29276.e9","article-title":"Characteristics and outcomes of squamous cell carcinoma and other cutaneous malignancies in epidermolysis bullosa: a systematic review","volume":"36","author":"Kim","year":"2023","journal-title":"Adv. Skin Wound Care"},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF01844351","article-title":"Zungenkrebs als Folgezustand bei einem Falle von Epidermolysis bullosa (dystrophische Form)","volume":"116","author":"Klausner","year":"1913","journal-title":"Arch. F\u00fcr Dermatol. Syph."},{"issue":"8","key":"10.1016\/j.humimm.2024.110805_b0060","doi-asserted-by":"crossref","first-page":"adv00523","DOI":"10.2340\/00015555-3875","article-title":"Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study","volume":"101","author":"Robertson","year":"2021","journal-title":"Acta Derm. Venereol."},{"issue":"7","key":"10.1016\/j.humimm.2024.110805_b0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-4632.2009.03910.x","article-title":"Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl","volume":"48","author":"Shivaswamy","year":"2009","journal-title":"Int. J. Dermatol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: the national EB registry experience, 1986\u20132006","volume":"60","author":"Fine","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0075","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/0008-5472.CAN-15-1348","article-title":"Injury-driven stiffening of the dermis expedites skin carcinoma progression","volume":"76","author":"Mittapalli","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.humimm.2024.110805_b0080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2230.2002.01130.x","article-title":"Epidermolysis bullosa and cancer","volume":"27","author":"Mallipeddi","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"issue":"5","key":"10.1016\/j.humimm.2024.110805_b0085","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0190-9622(08)81509-5","article-title":"Nonmelanoma skin cancer in the United States: incidence","volume":"30","author":"Miller","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.humimm.2024.110805_b0090","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1470-2045(08)70178-5","article-title":"Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study","volume":"9","author":"Brantsch","year":"2008","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.humimm.2024.110805_b0095","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jid.2017.06.025","article-title":"Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study","volume":"137","author":"Eigentler","year":"2017","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1011-1344(01)00199-3","article-title":"UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer","volume":"63","author":"de Gruijl","year":"2001","journal-title":"J. Photochem. Photobiol. B"},{"issue":"455","key":"10.1016\/j.humimm.2024.110805_b0105","doi-asserted-by":"crossref","first-page":"eaas9668","DOI":"10.1126\/scitranslmed.aas9668","article-title":"APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa","volume":"10","author":"Cho","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.humimm.2024.110805_b0110","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.humimm.2024.110805_b0115","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/jid.2009.31","article-title":"The effect of having an affected parent or sibling on invasive and in situ skin cancer risk in Sweden","volume":"129","author":"Hussain","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0120","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s12325-023-02749-x","article-title":"Oleogel-S10 in dystrophic epidermolysis bullosa: a case series evaluating the impact on wound burden over two years","volume":"41","author":"Torres Pradilla","year":"2024","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0125","first-page":"e12983","article-title":"Mechanism of Oleogel-S10: a triterpene preparation for the treatment of epidermolysis bullosa","volume":"32","author":"Schwieger-Briel","year":"2019","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/bjd\/ljac001","article-title":"Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study","volume":"188","author":"Kern","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjd.14104","article-title":"Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines","volume":"174","author":"Mellerio","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0140","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2133.2005.06783.x","article-title":"Topical photodynamic therapy for Bowen\u2019s disease of the digit in epidermolysis bullosa: correspondence","volume":"153","author":"Souza","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archderm.1989.01670180069008","article-title":"Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa","volume":"125","author":"Tyring","year":"1989","journal-title":"Arch. Dermatol."},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0150","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF00917477","article-title":"Patients with severe forms of inherited epidermolysis bullosa exhibit decreased lymphokine and monokine production","volume":"10","author":"Chopra","year":"1990","journal-title":"J. Clin. Immunol."},{"issue":"42","key":"10.1016\/j.humimm.2024.110805_b0155","doi-asserted-by":"crossref","first-page":"e1528","DOI":"10.1097\/MD.0000000000001528","article-title":"Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa","volume":"94","author":"Annicchiarico","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.humimm.2024.110805_b0160","first-page":"961","article-title":"Canakinumab in recessive dystrophic epidermolysis bullosa: a novel unexpected weapon for non-healing wounds?","volume":"34","author":"Annicchiarico","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"10","key":"10.1016\/j.humimm.2024.110805_b0165","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3390\/ijms17101625","article-title":"Autoimmunity and cytokine imbalance in inherited epidermolysis bullosa","volume":"17","author":"Esposito","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110805_b0170","article-title":"IL-6\/IL-10 Ratio as A prognostic and predictive marker of the severity of inherited epidermolysis bullosa","author":"Tampoia","year":"2017","journal-title":"Iranian Journal of Immunology"},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0175","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cia2.12230","article-title":"New insight of itch mediators and proinflammatory cytokines in epidermolysis bullosa","volume":"5","author":"Nguyen","year":"2022","journal-title":"J. Cutan. Immunol. Allergy"},{"key":"10.1016\/j.humimm.2024.110805_b0180","first-page":"1346","article-title":"Successful treatment of multicentric Castleman\u2019s disease associated with dystrophic epidermolysis bullosa using anti\u2010interleukin\u20106 receptor antibody","author":"Naruse","year":"2024","journal-title":"J. Dermatol."},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0185","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1709111115","article-title":"Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa","volume":"115","author":"Nystr\u00f6m","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0190","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1600-0625.2012.01502.x","article-title":"High genetic diversity of Staphylococcus aureus strains colonizing patients with epidermolysis bullosa","volume":"21","author":"Van Der Kooi-Pol","year":"2012","journal-title":"Exp. Dermatol."},{"issue":"8","key":"10.1016\/j.humimm.2024.110805_b0195","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0305-4179(95)00047-F","article-title":"Microbial colonization of large wounds","volume":"21","author":"Vindenes","year":"1995","journal-title":"Burns"},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0200","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/jid.2012.347","article-title":"High anti-staphylococcal antibody titers in patients with epidermolysis bullosa relate to long-term colonization with alternating types of staphylococcus aureus","volume":"133","author":"Van Der Kooi-Pol","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41423-020-00541-3","article-title":"Macrophages and the maintenance of homeostasis","volume":"18","author":"Mosser","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"10","key":"10.1016\/j.humimm.2024.110805_b0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ijms24108757","article-title":"Monocyte differentiation and heterogeneity: inter-subset and interindividual differences","volume":"24","author":"Williams","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/acsptsci.3c00336","article-title":"Investigating inflammatory markers in wound healing: understanding implications and identifying artifacts","volume":"7","author":"Mahmoud","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"10","key":"10.1016\/j.humimm.2024.110805_b0220","doi-asserted-by":"crossref","first-page":"e13115","DOI":"10.1111\/cpr.13115","article-title":"Role of the CCL2-CCR2 signalling axis in cancer: mechanisms and therapeutic targeting","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Prolif."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0225","first-page":"1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0230","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-Associated Macrophages: From Mechanisms to Therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0235","doi-asserted-by":"crossref","first-page":"e20191869","DOI":"10.1084\/jem.20191869","article-title":"Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer","volume":"217","author":"Etzerodt","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.humimm.2024.110805_b0240","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice","author":"Jayasingam","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0245","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000343082","article-title":"Cutaneous squamous cell carcinoma developing from recessive dystrophic epidermolysis bullosa: a case report and an immunohistochemical study","volume":"4","author":"Tsukada","year":"2012","journal-title":"Case Rep. Dermatol."},{"key":"10.1016\/j.humimm.2024.110805_b0250","doi-asserted-by":"crossref","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.humimm.2024.110805_b0255","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1038\/s41598-020-71794-1","article-title":"Cells from discarded dressings differentiate chronic from acute wounds in patients with Epidermolysis Bullosa","volume":"10","author":"Fuentes","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0260","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/life12020213","article-title":"Immune disregulation in cutaneous squamous cell carcinoma of patients with recessive dystrophic epidermolysis bullosa: a single pilot study","volume":"12","author":"Filoni","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.humimm.2024.110805_b0265","doi-asserted-by":"crossref","first-page":"1160719","DOI":"10.3389\/fimmu.2023.1160719","article-title":"Advances in the role of STAT3 in macrophage polarization","volume":"14","author":"Xia","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.humimm.2024.110805_b0270","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1346-8138.2005.tb00906.x","article-title":"Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma","volume":"32","author":"Suiqing","year":"2005","journal-title":"J. Dermatol."},{"issue":"46","key":"10.1016\/j.humimm.2024.110805_b0275","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1038\/onc.2011.180","article-title":"Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma","volume":"30","author":"Watt","year":"2011","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.humimm.2024.110805_b0280","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/bjd.18639","article-title":"STAT3 targeting in dystrophic epidermolysis bullosa","volume":"182","author":"Mittapalli","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0285","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jid.2020.08.022","article-title":"Targeting the jak\/signal transducer and activator of transcription 3 pathway with ruxolitinib in a mouse model of recessive dystrophic epidermolysis bullosa-squamous cell carcinoma","volume":"141","author":"Jack\u00f3w","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.110805_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155059","article-title":"STAT3-driven hematopoiesis and lymphopoiesis abnormalities are dependent on serine phosphorylation","volume":"130","author":"Balic","year":"2020","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0295","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1093\/bjd\/ljad174.042","article-title":"P21 Tyrosine and serine STAT3 phosphorylation drives cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa as demonstrated using a 3D in vitro model","volume":"189","author":"Llopis-Hernandez","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"10","key":"10.1016\/j.humimm.2024.110805_b0300","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0305","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2020.0304","article-title":"Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa","volume":"156","author":"Piccerillo","year":"2020","journal-title":"JAMA Dermatol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0310","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/jdv.15835","article-title":"Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa","volume":"34","author":"Reimer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0315","doi-asserted-by":"crossref","first-page":"e238966","DOI":"10.1136\/bcr-2020-238966","article-title":"Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa","volume":"14","author":"Duong","year":"2021","journal-title":"BMJ Case Rep."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0320","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1159\/000508933","article-title":"Induced remission of metastatic squamous cell carcinoma with an immune checkpoint inhibitor in a patient with recessive dystrophic epidermolysis bullosa","volume":"13","author":"Khaddour","year":"2020","journal-title":"Case Rep. Oncol."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0325","first-page":"295","article-title":"Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa","volume":"21","author":"Vasilev","year":"2023","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/j.humimm.2024.110805_b0330","doi-asserted-by":"crossref","first-page":"adv4870","DOI":"10.2340\/actadv.v103.4870","article-title":"Variable outcome of immunotherapy in advanced multiple cutaneous squamous cell carcinomas in two patients with recessive dystrophic epidermolysis bullosa","volume":"103","author":"Trefzer","year":"2023","journal-title":"Acta Derm. Venereol"},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0335","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/cancers16020471","article-title":"Epidermolysis-bullosa-associated squamous cell carcinomas support an immunosuppressive tumor microenvironment: prospects for immunotherapy","volume":"16","author":"Rafei-Shamsabadi","year":"2024","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0340","doi-asserted-by":"crossref","first-page":"e002057","DOI":"10.1136\/jitc-2020-002057","article-title":"Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma","volume":"9","author":"Zakharia","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.humimm.2024.110805_b0345","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.humimm.2024.110805_b0350","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-18-2661","article-title":"Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa\u2013associated squamous cell carcinoma","volume":"25","author":"Atanasova","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.humimm.2024.110805_b0355","doi-asserted-by":"crossref","unstructured":"C. A. A. Lee et al., \u2018Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa-Associated Cutaneous Squamous Cell Carcinoma\u2019, J. Invest. Dermatol., p. S0022202X24000228, Jan. 2024, doi: 10.1016\/j.jid.2023.11.025.","DOI":"10.1016\/j.jid.2023.11.025"},{"key":"10.1016\/j.humimm.2024.110805_b0360","unstructured":"\u2018Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) Associated Advances\/Metastatic Squamous Cell Carcinoma (SCC)\u2019, presented at the 32nd Congress of the European Academy of Dermatology and Venereology, Berlin, Oct. 2023. [Online]. Available: https:\/\/cure-eb.org\/wp-content\/uploads\/2023\/10\/Efficacy-and-Safety-of-Rigosertib-in-Patients-with-Recessive-Dystrophic-Epidermolysis-Bullosa.pdf."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0365","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/ijms23021007","article-title":"Transcriptome-guided drug repurposing for aggressive SCCs","volume":"23","author":"Zauner","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0370","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/ijms23031813","article-title":"The human microbiota and skin cancer","volume":"23","author":"Woo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.110805_b0375","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1038\/ncomms6932","article-title":"Innate sensing of microbial products promotes wound-induced skin cancer","volume":"6","author":"Hoste","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0380","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1525-1470.2009.01070.x","article-title":"Common wound colonizers in patients with epidermolysis bullosa","volume":"27","author":"Brandling-Bennett","year":"2010","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.humimm.2024.110805_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110259","article-title":"Knockdown of HMGB1 inhibits the crosstalk between oral squamous cell carcinoma cells and tumor-associated macrophages","volume":"119","author":"Wen","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/pde.14444","article-title":"Characterization of wound microbes in epidermolysis bullosa: results from the epidermolysis bullosa clinical characterization and outcomes database","volume":"38","author":"Levin","year":"2021","journal-title":"Pediatr. Dermatol."},{"issue":"9","key":"10.1016\/j.humimm.2024.110805_b0395","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/exd.14615","article-title":"T-cell activation and bacterial infection in skin wounds of recessive dystrophic epidermolysis bullosa patients","volume":"31","author":"Alexeev","year":"2022","journal-title":"Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0400","first-page":"472","article-title":"Staphylococcus aureus and squamous cell carcinoma of the skin","volume":"18","author":"Kullander","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol"},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0405","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/cancers12030541","article-title":"Molecular profiling of keratinocyte skin tumors links staphylococcus aureus overabundance and increased human \u03b2-defensin-2 expression to growth promotion of squamous cell carcinoma","volume":"12","author":"Madhusudhan","year":"2020","journal-title":"Cancers"},{"issue":"5716","key":"10.1016\/j.humimm.2024.110805_b0410","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1126\/science.1106209","article-title":"Type VII collagen is required for ras-driven human epidermal tumorigenesis","volume":"307","author":"Ortiz-Urda","year":"2005","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.humimm.2024.110805_b0415","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/sj.jid.5700878","article-title":"Patients with recessive dystrophic epidermolysis bullosa develop squamous-cell carcinoma regardless of type VII collagen expression","volume":"127","author":"Pourreyron","year":"2007","journal-title":"J. Invest. Dermatol."},{"issue":"3\u20134","key":"10.1016\/j.humimm.2024.110805_b0420","first-page":"221","article-title":"Cytoplasmic expression of type VII collagen is related to prognosis in patients with esophageal squamous cell carcinoma","volume":"71","author":"Baba","year":"2007","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0425","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejso.2008.01.025","article-title":"Clinical significance of LAMB3 and COL7A1 mRNA in esophageal squamous cell carcinoma","volume":"35","author":"Kita","year":"2009","journal-title":"Eur. J. Surg. Oncol. EJSO"},{"key":"10.1016\/j.humimm.2024.110805_b0430","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.1609860","article-title":"Prognostic value of highly expressed type VII collagen (COL7A1) in patients with gastric cancer","volume":"27","author":"Oh","year":"2021","journal-title":"Pathol. Oncol. Res."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0435","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3892\/ol.2023.13663","article-title":"Collagen type VII \u03b11 chain: a promising prognostic and immune infiltration biomarker of pancreatic cancer","volume":"25","author":"Ding","year":"2023","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0440","doi-asserted-by":"crossref","first-page":"djv293","DOI":"10.1093\/jnci\/djv293","article-title":"Suppression of TGF\u03b2 and angiogenesis by type VII collagen in cutaneous SCC","volume":"108","author":"Martins","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.humimm.2024.110805_b0445","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1371\/journal.pmed.0050114","article-title":"Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis","volume":"5","author":"Chan","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.humimm.2024.110805_b0450","doi-asserted-by":"crossref","first-page":"e20220486","DOI":"10.1590\/1678-7757-2022-0486","article-title":"Diagnostic potential of Type VII Collagen during oral carcinogenesis","volume":"31","author":"Poomsawat","year":"2023","journal-title":"J. Appl. Oral Sci."},{"issue":"10","key":"10.1016\/j.humimm.2024.110805_b0455","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.3390\/ijms22105104","article-title":"Impaired wound healing, fibrosis, and cancer: the paradigm of recessive dystrophic epidermolysis bullosa","volume":"22","author":"Tartaglia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.humimm.2024.110805_b0460","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.humimm.2024.110805_b0465","article-title":"Estimated spending on beremagene geperpavec for dystrophic epidermolysis bullosa","author":"Raymakers","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0470","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.20910","article-title":"The potential of gene therapy for recessive dystrophic epidermolysis bullosa","volume":"186","author":"Subramaniam","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"10.1016\/j.humimm.2024.110805_b0475","doi-asserted-by":"crossref","first-page":"e126243","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0480","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/dth.12305","article-title":"Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial","volume":"29","author":"El-Darouti","year":"2016","journal-title":"Dermatol. Ther."},{"issue":"9","key":"10.1016\/j.humimm.2024.110805_b0485","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0490","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","volume":"83","author":"Rashidghamat","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"22","key":"10.1016\/j.humimm.2024.110805_b0495","doi-asserted-by":"crossref","first-page":"e151922","DOI":"10.1172\/jci.insight.151922","article-title":"Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Kiritsi","year":"2021","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0500","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0505","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/archderm.1974.01630120044009","article-title":"Epidermolysis bullosa dystrophica with epidermal neoplasms","volume":"110","author":"Reed","year":"1974","journal-title":"Arch. Dermatol."},{"issue":"14","key":"10.1016\/j.humimm.2024.110805_b0510","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJM198010023031402","article-title":"Phenytoin therapy of recessive dystrophic epidermolysis bullosa: clinical trial and proposed mechanism of action on collagenase","volume":"303","author":"Bauer","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0515","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJM199207163270305","article-title":"Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa","volume":"327","author":"Caldwell-Brown","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.humimm.2024.110805_b0520","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF03401916","article-title":"Basic fibroblast growth factor: a missing link between collagen VII, increased collagenase, and squamous cell carcinoma in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Arbiser","year":"1998","journal-title":"Mol. Med."},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0525","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jid.2020.10.024","article-title":"Diversity of mechanisms underlying latent TGF-\u03b2 activation in recessive dystrophic epidermolysis bullosa","volume":"141","author":"Akasaka","year":"2021","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.humimm.2024.110805_b0530","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI34292","article-title":"A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy","volume":"118","author":"Fritsch","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110805_b0535","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/msb.2013.17","article-title":"Global remodelling of cellular microenvironment due to loss of collagen VII","volume":"9","author":"K\u00fcttner","year":"2013","journal-title":"Mol. Syst. Biol."},{"issue":"14","key":"10.1016\/j.humimm.2024.110805_b0540","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-11-2996","article-title":"Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa","volume":"72","author":"Ng","year":"2012","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.humimm.2024.110805_b0545","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms","volume":"7","author":"Nystr\u00f6m","year":"2015","journal-title":"EMBO Mol. Med."},{"issue":"8","key":"10.1016\/j.humimm.2024.110805_b0550","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1172\/JCI68127","article-title":"Collagen VII plays a dual role in wound healing","volume":"123","author":"Nystr\u00f6m","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.110805_b0555","unstructured":"D. Kiritsi, \u2018Losartan for RDEB trial \u2013 results and international perspectives\u2019, presented at the EB2020 1st World Congress on Epidermolysis Bullosa, Jan. 2020."},{"key":"10.1016\/j.humimm.2024.110805_b0560","unstructured":"D. Kiritsi, \u2018Losartan Drug Repurposing for REFLECT 2 Phase III Clinical Trial in Epidermolysis bullosa\u2019. [Online]. Available: https:\/\/www.midas-pharma.com\/media\/expose_losartan_eb2020_midas_pharma.pdf."},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0565","doi-asserted-by":"crossref","first-page":"e14279","DOI":"10.1111\/dth.14279","article-title":"Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa","volume":"33","author":"Inamadar","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"7","key":"10.1016\/j.humimm.2024.110805_b0570","doi-asserted-by":"crossref","first-page":"e15515","DOI":"10.1111\/dth.15515","article-title":"Losartan treatment improves recessive dystrophic epidermolysis bullosa: a case series","volume":"35","author":"Pourani","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0575","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjd.19421","article-title":"Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma","volume":"184","author":"Dayal","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.humimm.2024.110805_b0580","doi-asserted-by":"crossref","first-page":"625","DOI":"10.14740\/jocmr2606w","article-title":"Systemic sclerosis and malignancy: a review of current data","volume":"8","author":"Zeineddine","year":"2016","journal-title":"J. Clin. Med. Res."},{"issue":"9","key":"10.1016\/j.humimm.2024.110805_b0585","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jdcr.2020.07.012","article-title":"High-risk cutaneous squamous cell carcinoma with intravascular involvement recurs in a patient with systemic sclerosis","volume":"6","author":"Hoverson","year":"2020","journal-title":"JAAD Case Rep."},{"issue":"6","key":"10.1016\/j.humimm.2024.110805_b0590","first-page":"970","article-title":"Progressive systemic sclerosis and pulmonary malignancy","volume":"9","author":"Trotta","year":"1982","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.humimm.2024.110805_b0595","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archderm.1988.01670050081027","article-title":"Tissue stress and tumor promotion: possible relevance to epidermolysis bullosa","volume":"124","author":"Goldberg","year":"1988","journal-title":"Arch. Dermatol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0600","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archderm.1990.01670250084014","article-title":"Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. implications for carcinogenesis","volume":"126","author":"Smoller","year":"1990","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.humimm.2024.110805_b0605","doi-asserted-by":"crossref","first-page":"1211505","DOI":"10.3389\/fimmu.2023.1211505","article-title":"Inflammation-mediated fibroblast activation and immune dysregulation in collagen VII-deficient skin","volume":"14","author":"Anderson-Crannage","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.110805_b0610","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL-1-induced JAK\/STAT signaling is antagonized by TGF-\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.humimm.2024.110805_b0615","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2010.09924.x","article-title":"Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma","volume":"163","author":"Kivisaari","year":"2010","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0620","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/bjd\/ljad335","article-title":"MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas","volume":"190","author":"Illmer","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.humimm.2024.110805_b0625","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jdv.19488","article-title":"Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma","volume":"38","author":"Welponer","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888592400065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019888592400065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:01:18Z","timestamp":1781568078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019888592400065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S019888592400065X"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110805","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.110805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.","name":"copyright","label":"Copyright"}],"article-number":"110805"}}